logo-loader
AIM:DEST

Destiny Pharma PLC

Receive alerts
Market:
AIM
Price
-
Day Change
-
Market Cap:
-
52 weeks high
-
52 weeks low
-

In brief

Destiny Pharma PLC is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections.

The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.